AMP‐Activated Protein Kinase (AMPK)

AMPK (AMP-activated protein kinase) is a protein kinase that acts as a sensor of cellular energy status by monitoring the levels of adenine nucleotides, especially adenosine monophosphate (AMP) and adenosine-5¢-triphosphate (ATP). When activated by falling cellular energy status, it acts to restore energy balance by switching on ATP-producing catabolic pathways, while switching off any energy-requiring processes (such as biosynthesis, cell growth and division) that are not essential for short-term survival. AMPK is also regulated by hormones and cytokines that control energy balance at the whole body level.

Keywords: energy balance; protein kinase; metabolism; AMP; ATP

Figure 1. Schematic showing role of AMPK in the regulation of cellular energy balance. Catabolism normally maintains a high ratio of ATP:ADP in the cell (typically 10:1). Inhibition of catabolism (e.g. starvation for glucose or oxygen), or acceleration of ATP consumption (e.g. muscle contraction) would cause an increase in the ADP:ATP ratio that is converted by the enzyme adenylate kinase into an even larger rise in AMP:ATP. Rising AMP coupled with falling ATP switches on the AMPK system, which then activates alternate catabolic pathways and switches off ATP-consuming processes to restore energy balance.
Figure 2. Structure of the core of the mammalian AMPK complex. For the protein, only the course of the polypeptide backbone is shown in ‘cartoon’ view; for AMP, atoms are shown as ‘spheres’, with carbon green, nitrogen blue, oxygen red, phosphorus orange and hydrogen omitted. The C-terminal domain of the subunit (yellow) is on the left, with the C-terminal region of the subunit (red) wrapping around it. The interaction between the complex and the subunits is mainly via the three-stranded -sheet at left centre, with two strands (red) from and one (blue-green) from . The structure contains the entire 1 subunit, with the N-terminal region in salmon pink followed by the four CBS repeats: CBS1 (blue-green), CBS2 (magenta), CBS3 (dark blue) and CBS4 (orange). Three molecules of AMP are present, one (AMP2) in the cleft between CBS1 and CBS2, and two (AMP1 and AMP3, the latter being nonexchangeable) in the cleft between CBS3 and CBS4. All three molecules of AMP are oriented with their phosphate groups towards the central aqueous channel, via which the nucleotides may enter and leave. The image was created using MacPyMol using published atomic coordinates (Xiao et al., 2007).
Figure 3. Summary of metabolic stresses, drugs and cytokines that regulate AMPK.
close
 References
    Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304–1305.
    Hawley SA, Boudeau J, Reid JL et al. (2003) Complexes between the LKB1 tumor suppressor, STRADa/b and MO25a/b are upstream kinases in the AMP-activated protein kinase cascade. Journal of Biology 2: 28.
    Hawley SA, Pan DA, Mustard KJ et al. (2005) Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metabolism 2: 9–19.
    Luptak I, Shen M, He H et al. (2007) Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. Journal of Clinical Investigation 117: 1432–1439.
    McCrimmon RJ, Shaw M, Fan X et al. (2008) Key role for AMP-activated protein kinase in the ventromedial hypothalamus in regulating counterregulatory hormone responses to acute hypoglycemia. Diabetes. 57: 444–450.
    Polekhina G, Gupta A, van Denderen BJ et al. (2005) Structural basis for glycogen recognition by AMP-activated protein kinase. Structure (Camb) 13: 1453–1462.
    Sanders MJ, Grondin PO, Hegarty BD, Snowden MA and Carling D (2007) Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochemical Journal 403: 139–148.
    Scott JW, Hawley SA, Green KA et al. (2004) CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. Journal of Clinical Investigation 113: 274–284.
    Xiao B, Heath R, Saiu P et al. (2007) Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 449: 496–500.
    Zhou G, Myers R, Li Y et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. Journal of Clinical Investigation 108: 1167–1174.
 Further Reading
    Arad M, Seidman CE and Seidman JG (2007) AMP-activated protein kinase in the heart: role during health and disease. Circulation Research 100: 474–488.
    Carling D (2004) The AMP-activated protein kinase cascade–a unifying system for energy control. Trends in Biochemical Sciences 29: 18–24.
    Hardie DG (2007) AMP-activated protein kinase as a drug target. Annual Review of Pharmacology and Toxicology 47: 185–210.
    Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nature Reviews. Molecular Cell Biology 8: 774–785.
    Kahn BB, Alquier T, Carling D and Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metabolism 1: 15–25.
    Kemp BE (2004) Bateman domains and adenosine derivatives form a binding contract. Journal of Clinical Investigation 113: 182–184.
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Hardie, D Grahame(Sep 2008) AMP‐Activated Protein Kinase (AMPK). In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0021030]